28 October 2021 - The marketing authorisation application seeks approval of ruxolitinib cream for the treatment of adolescent and adult patients with non-segmental vitiligo with facial involvement.

Incyte today announced the validation of the European marketing authorisation application for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement.

Read Incyte press release